Vertex Pharmaceuticals, Inc.

Viro Chem Pharma, Inc.

Vertex Pharmaceuticals (canada) Incorporated

Thumkunta Jagadeeswar Reddy

Sanjoy Kumar Das

Michel Gallant

Laval Chan Chun Kong

Carl Poisson

Yeeman K Ramtohul

Evelyne Dietrich

Frederic Vallee

Louis Vaillancourt

Oswy Z Pereira

Bingcan Liu

Julien Martel

Caroline Cadilhac

Nghe Nguyen-Ba

Mohammad Arshad Siddiqui

Wuyi Wang

Melanie Proulx

Jean Bedard

Mark Thomas Miller

Jinglan Zhou

Sara Sabina Hadida Ruah

Thomas Cleveland

Timothy Richard Coon

Claudio F Sturino

Prasuna Paraselli

Brett C Bookser

Jeremy J Clemens

Christophe Moinet

Marc Courchesne

Minson Baek

Liliane Halab

Nghe Nguyen Ba

Zhang Ming-Qiang

Constanin Yannopoulos

Ming-Qiang Zhang

William Schulz Bechara

Julie Laterreur

Peter Diederik Jan Grootenhuis

Peter Grootenhuis

Lino J Valdez

Constantin G Yannopoulos

Vito Melillo

Jean-Francois Truchon

Mingqiang Zhang

Stephanie Lessard

Bettina Hamelin

Lino Valdez

Jean-Francois Lévesque

Mélanie Proulx

Yeeman Ramtohul

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

Modulators of cystic fibrosis transmembrane conductance regulator

The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I:  The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.

Mannose derivatives for treating bacterial infections

2,7-dibromospiro[fluorene-9,4'-piperidine] compounds

The compounds represented by Formula (I) or pharmaceutically acceptable salts thereof: with U, W, X, Y, Z, p and ring A as defined in claim. Those compounds are useful for the treatment or prevention of bacteria infections. The variables of Formula (I) are as described herein. Pharmaceutically acceptable compositions comprise the compounds of Formula (I) or pharmaceutically acceptable salts thereof and pharmaceutically acceptable carriers, adjuvants, or vehicles. Methods of treating bacteria infections employ such compounds or pharmaceutically acceptable salts thereof. 

The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I:  The invention also provides processes for making the compounds described herein. Furthermore, the present invention provides a composition comprising the compounds described herein, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The present invention also provides methods of treating or preventing bacteria infection in a subject, comprising administering to the subject an effective amount of the compound or the composition described herein.

Compounds represented by formula: wherein X, Y and Z are as defined herein, pharmaceutically acceptable salts thereof, and related compounds, are suitable for use in treating or preventing a Flaviviridae viral infection in a host.

Compounds and methods for the treatment or prevention of flavivirus infections

The present invention provides novel compounds represented by formula I: or pharmaceutically acceptable salts thereof useful for treating flaviviridae viral infection.

[object Object]

Compounds of formula I wherein R, R, R, Rand Rare as defined herein, or pharmaceutically acceptable salts, hydrates or solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.

Spirohydantoin compounds and methods for the modulation of chemokine receptor activity

Compounds of formula I wherein X, Y, Z, W, Rand Ras defined herein, or pharmaceutically acceptable salts, hydrates or solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.

Spiro compounds and methods for the modulation of chemokine receptor activity

Growing community of inventors

Pierrefonds, Canada

Thumkunta Jagadeeswar Reddy